- Responsible for conception and design of complex molecular assays - Worked closely with clinical staff for the implementation of complex molecular assays - Drafted and edited SOPs, EOPs, validation protocols, validation reports, and other technical documents - Delivered technical talks to internal stakeholders - Mediated interactions between TAI and external vendors to secure products and technologies in a timely fashion - Educated clinical lab staff with necessary… Show more - Responsible for conception and design of complex molecular assays - Worked closely with clinical staff for the implementation of complex molecular assays - Drafted and edited SOPs, EOPs, validation protocols, validation reports, and other technical documents - Delivered technical talks to internal stakeholders - Mediated interactions between TAI and external vendors to secure products and technologies in a timely fashion - Educated clinical lab staff with necessary scientific background to allow for full understanding and troubleshooting of job functions Show less

- Logged data and generated reports using a CRM (Salesforce) - Worked closely with Scientists, Purchasing, EHS, and Facilities to prospect, quote, and close sales - Delivered technical and basic customer support by facilitating communications between customers and internal company experts

- Responsible for conception and design of studies - Developed and verified multiplex qPCR miRNA assays for all functional human miRNAs, and CRISPR genome editing for miRNAs - Responsible for drafting complex procedural SOPs and protocols - Delivered technical presentations to a wide variety of audiences

- Worked with both prostate and non-small cell lung cancer cell lines and primary tissue samples- Showed the contribution of TGF-β-bFGF-FGFR1 in prostate cancer bone metastasis- Demonstrated that systemic inhibition of bFGF might be an effective treatment for targeting prostate/lung cancer bone metastasis

- Demonstrated that p-α-CaMKII levels are increased in primary human osteosarcoma tissues and in aggressive human osteosarcoma cell lines. - α-CaMKII KO in osteosarcoma cell lines decreases proliferation, motility and invasion, while α-CaMKII overexpression increases these tumorigenic properties.- Identified a novel signaling pathway demonstrating the paracrine and autocrine effects of α-CaMKII-induced VEGF on human osteosarcoma. - Demonstrated that the inhibition of both α-CaMKII… Show more - Demonstrated that p-α-CaMKII levels are increased in primary human osteosarcoma tissues and in aggressive human osteosarcoma cell lines. - α-CaMKII KO in osteosarcoma cell lines decreases proliferation, motility and invasion, while α-CaMKII overexpression increases these tumorigenic properties.- Identified a novel signaling pathway demonstrating the paracrine and autocrine effects of α-CaMKII-induced VEGF on human osteosarcoma. - Demonstrated that the inhibition of both α-CaMKII and VEGF dramatically decreases the aggressiveness of osteosarcoma in vitro and in vivo. - Created a new clinically relevant osteosarcoma metastasis model by surgically amputating the tumor containing hind limb of mice and monitoring the development of pulmonary metastases.- Discovered that a novel treatment regimen of Tamoxifen and Avastin could dramatically reduce osteosarcoma metastases. Show less